---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-26-000030"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2026-07-27T23:29:38+00:00"
generated_at: "2026-07-28T10:05:44.872914+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nautilus Q2 net loss $14.5M; first revenue $0.2M; delays broadscale assay, accelerates proteoforms

## Summary
- Revenue of $0.2M from MJFF grant and first Early Access customer; net loss $14.5M vs $15.0M YoY.
- Operating expenses $15.9M, down 7% YoY; cash, equivalents and investments $129.2M.
- Voyager platform pre-orders expected early 2027, shipments mid-2027; proteoform kits GA mid-2027.
- Broadscale assay delayed; no 2027 GA timeline; company reallocating resources to proteoforms.
- AKT1 proteoform assay Early Access late 2026; second oncology assay mid-2027.

## SEC filing metadata
- accession: 0001808805-26-000030
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2026-07-27T23:29:38+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000030/0001808805-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000030/naut-20260728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-26-000030
- JSON: https://secwatch.observer/filing/0001808805-26-000030.json
- Plain text: https://secwatch.observer/filing/0001808805-26-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.